References
- 1. Avrillon V, Locatelli-Sanchez M, Folliet L, Carbon-naux M, Perino E, Fossard G, et al. Lung cancer may increase serum procalcitonin level. Infect Disord Drug Targets. 2015;15(1):57-63. DOI: 10.2174/1871526515 666150320162950
- 2. Kaczka K, Mikosiński S, Fendler W, Celnik A, Pomorski L. Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection. Adv Clin Exp Med. 2012;21(2):169-78.
- 3. Rami D, La Bianca M, Agostinis C, Zauli G, Radillo O, Bulla R. The first trimester gravid serum regulates procalcitonin expression in human macrophages skewing their phenotype in vitro. Mediators Inflamm. 2014;2014:248963. DOI: 10.1155/2014/24896310.1155/2014/248963
- 4. Fung AWS, Beriault D, Diamandis EP, Burnham CD, Dorman T, Downing M, et al. The Role of Procalcitonin in Diagnosis of Sepsis and Antibiotic Stewardship: Opportunities and Challenges. Clin Chem. 2017;63(9):1436-41. DOI: 10.1373/clinchem.2017.27229410.1373/clinchem.2017.272294
- 5. Schuetz P, Bretscher C, Bernasconi L, Mueller B. Overview of procalcitonin assays and procalcitonin-guided protocols for the management of patients with infections and sepsis. Expert Rev Mol Diagn. 2017;17(6):593-601. DOI: 10.1080/14737159.2017.132429910.1080/14737159.2017.1324299
- 6. Jiang L, Feng B, Gao D, Zhang Y. Plasma concentrations of copeptin, C-reactive protein and procalcitonin are positively correlated with APACHE II scores in patients with sepsis. J Int Med Res. 2015;43(2):188-95. DOI: 10.1177/030006051456113610.1177/0300060514561136
- 7. Jain S, Sinha S, Sharma SK, Samantaray JC, Aggrawal P, Vikram NK, et al. Procalcitonin as a prognostic marker for sepsis: a prospective observational study. BMC Res Notes. 2014;7(1):458. DOI: 10.1186/1756-0500-7-45810.1186/1756-0500-7-458
- 8. Anand D, Das S, Bhargava S, Srivastava LM, Garg A, Tyagi N, et al. Procalcitonin as a rapid diagnostic biomarker to differentiate between culture-negative bacterial sepsis and systemic inflammatory response syndrome: a prospective, observational, cohort study. J Crit Care. 2015;30(1):218.e7-12. DOI: 10.1016/j. jcrc.2014.08.017
- 9. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Crit Care Med. 2013;41(2):580-637. DOI: 10.1097/CCM.0b013e31827e83af10.1097/CCM.0b013e31827e83af
- 10. Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95-107. DOI: 10.1016/S1473-3099(17)30592-310.1016/S1473-3099(17)30592-3
- 11. Quach S, Hennessy DA, Faris P, Fong A, Quan H, Doig C. A comparison between the APACHE II and Charlson Index Score for predicting hospital mortality in critically ill patients. BMC Health Serv Res. 2009;9:129-36. DOI: 10.1186/1472-6963-9-12910.1186/1472-6963-9-129273174419643010
- 12. Yang CJ, Chen J, Phillips AR, Windsor JA, Petrov MS. Predictors of severe and critical acute pancreatitis: a systematic review. Dig Liver Dis. 2014;46(5):446-51. DOI: 10.1016/j.dld.2014.01.15810.1016/j.dld.2014.01.15824646880
- 13. Staubli SM, Oertli D, Nebiker CA. Laboratory markers predicting severity of acute pancreatitis. Crit Rev Clin Lab Sci. 2015;52(6):273-83. DOI: 10.3109/10408363.2015.105165910.3109/10408363.2015.105165926173077
- 14. Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic targe. Br J Pharmacol. 2010;159(2):253-64. DOI: 10.1111/j.1476-5381.2009.00433.x10.1111/j.1476-5381.2009.00433.x282534920002097
- 15. Ryu JA, Yang JH, Lee D, Park CM, Suh GY, Jeon K, et al. Clinical Usefulness of Procalcitonin and C-Reactive Protein as Outcome Predictors in Critically Ill Patients with Severe Sepsis and Septic Shock. PLoS One. 2015;10(9):e0138150. DOI: 10.1371/journal. pone.0138150
- 16. Trásy D, Molnár Z. Procalcitonin - Assisted Antibiotic Strategy in Sepsis. EJIFCC. 2017;28(2):104-13.
- 17. Zhao JJ, Lou XL, Chen HW, Zhu FT, Hou YQ. Diagnostic value of decoy receptor 3 combined with procalcitonin and soluble urokinase-type plasminogen activator receptor for sepsis. Cell Mol Biol Lett. 2018;23:22-31. DOI: 10.1186/s11658-018-0087-z10.1186/s11658-018-0087-z594162129760745
- 18. Tuzun A, Uygun A, Yesilova Z, Ozel AM, Erdil A, Yaman H, et al. Leptin levels in the acute stage of ulcerative colitis. J Gastroenterol Hepatol. 2004;19(4):429-32. DOI: 10.1111/j.1440-1746.2003.03300.x10.1111/j.1440-1746.2003.03300.x15012781
- 19. Chooklin S, Hranat O. Intraarterial therapy, interleukins and oxidative stress parameters in acute pancreatitis patients. Pancreatology. 2013;13(2):e20. DOI: 10.1016/j. pan.2012.12.124
- 20. Liu HH, Guo JB, Geng Y, Su L. Procalcitonin: present and future. Ir J Med Sci. 2015;184(3):597-605. DOI: 10.1007/s11845-015-1327-010.1007/s11845-015-1327-026159431
- 21. Huang HL, Nie X, Cai B, Tang JT, He Y, Miao Q, et al. Procalcitonin levels predict acute kidney injury and prognosis in acute pancreatitis: a prospective study. PLoS One. 2013;8(12):e82250. DOI: 10.1371/journal. pone.0082250
- 22. Wu JY, Lee SH, Shen CJ, Hsieh YC, Yo PH, Cheng HY, et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum. 2014;64(9):3034-42. DOI: 10.1002/art.3451210.1002/art.3451222605405